Clinical stage biopharmaceutical company focused on the treatment of cancer using cell therapy and combination approaches. Tessa’s Virus-Specific T cell (VST) platform redirects body’s potent anti-viral immune response to recognize and kill cancer cells and has shown promising efficacy and safety in multiple solid tumor indications. The Company has an advanced clinical pipeline (ongoing Ph III trial – nasopharyngeal cancer, Ph I trial – cervical cancer, moving into Ph II), with multiple other assets (targeting liver, lung, breast, and head and neck cancer) entering the clinic in the near term. Key collaborators include Baylor College of Medicine, Parker Institute for Cancer Immunotherapy (first cell therapy partner) and St. Jude Children’s Research Hospital. Advanced manufacturing and logistics capabilities, with upcoming commercial manufacturing facility.
8 Temasek Boulevard, #24-02
Suntec Tower Three
Send Message to Request Information
Log in to download presentation, request a 1x1 meeting, view additional roadshows, and more.